Zoledronic acid 5 mg/100 mL bottle; solution for IV infusion. Paget’s disease of bone is characterized by greatly increased and disorderly bone remodeling. Excessive osteoclastic bone resorption is ...

The U.S. Food and Drug Administration (FDA) has approved Reclast® (zoledronic acid) Injection, the first and only once-yearly treatment for postmenopausal osteoporosis. Approximately 8 million women ...

EAST HANOVER, N.J., Oct. 16 Novartis announced today that new six-year data reinforce the long-term efficacy and safety profile of once-yearly Reclast® (zoledronic acid) injection in postmenopausal ...

Osteoporosis is a disease in which your bones lose their density and quality. It places you at a high risk of easily breaking a bone without experiencing a major trauma or injury. In good health, new ...

Reclast (zoledronic acid) is a medication that the Food and Drug Administration (FDA) has approved for preventing and treating osteoporosis in females after menopause, males, and individuals who take ...

Reclast (zoledronic acid or zoledronate) is approved by the Food and Drug Administration (FDA) to treat and prevent osteoporosis in males, females after menopause, and people taking glucocorticoids.

One major warning sign of osteoporosis is a “fragility fracture”—a broken bone caused by something minor like a simple fall.

(1) Reclast provides year-long bisphosphonate compliance with a single infusion. Reclast is the only yearly treatment approved to reduce the risk of fractures in areas of the body typically affected ...